VTUS Phase 3 data due May. SCMP sNDA filing soon + Pipeline updates for ASTM OXGN RVX IDRA ARIA

May 10, 2012 No Comments by
Ventrus Biosciences, Inc. (Nasdaq:VTUS) gave a pipeline update noting that initial top-line data from its Phase 3 trial of Diltiazem (VEN 307) in patients with Anal Fissures, is expected to be available in May 2012. Phase 3 data of Iferanserin (VEN 309) in patients with Hemorrhoidal Disease, is expected in late June or early July 2012.

Aastrom Biosciences, Inc. (Nasdaq:ASTM) announced that the first patient has been enrolled in the REVIVE Phase 3 clinical trial of ixmyelocel-T in the treatment of critical limb ischemia (CLI).

Sucampo Pharmaceuticals, Inc. (NASDAQ: SCMP) said that it expects to submit a sNDA during mid-2012 seeking priority review of lubiprostone for the treatment of opioid-induced bowel dysfunction (OBD) in patients with chronic non-cancer pain

OXiGENE, Inc. (Nasdaq: OXGN) said in its earnings release that it hopes to initiate its FACT 2, Phase 3 trial of ZYBRESTAT in patients with anaplastic thyroid cancer, during 4Q 2012.

Resverlogix Corp. (TSX:RVX) announced that dosing in its Phase 2b trial (SUSTAIN) of RVX-208 has been completed. Top line data are due in Q3 2012, while data from its Phase 3 ASSURE trial are due in Q1 2013.

Idera Pharmaceuticals, Inc. (NASDAQ: IDRA) said that it expects to complete its Phase 2 study of IMO-3100 in patients with psoriasis during 1H 2013.

ARIAD Pharmaceuticals, Inc.(NASDAQ: ARIA) reported financial results for the latest quarter and noted that both NDA and MAA filings are expected in 3Q 2012 for ponatinib, in patients with chronic myeloid leukemia (CML) and Philadelphia-chromosome positive acute lymphoblastic leukemia (Ph+ALL). In addition a Phase 3 trial of ponatinib in patients with newly diagnosed CML is also scheduled to start in the 3Q 2012. A Phase 2 trial of ponatinib in newly diagnosed patients with CML is now enrolling, while a Phase 2 trial in patients with Ph+ALL is also ongoing. Its Phase 2 trial in patients with CML who have failed imatinib is in advanced planning. The company also noted that it expects to move into the Phase 2 portion of its Phase 1/2 trial at approximately mid-year 2012 in its trial of AP26113 in ALK-positive and EGFR-positive lung cancer patients.

Dynavax Technologies Corporation (NASDAQ: DVAX)  announced the pricing of an underwritten public offering of 17.5m shares at a price to the public of $4.25 per share, for gross proceeds of approximately $74.4m, with an option to issue a further 2,625,000 additional shares of common stock to cover over-allotments.


Daily News

About the author

Currently residing in New Zealand, Mr. A.Burden holds a Master of Commerce in International Business from the University of Sydney and used these skills together with his passion for investing to establish BioPharmCatalyst in June 2010 as a tool for investing decisions in the US pharmaceutical market. He spends much of his free time mountain biking, playing squash and hiking.
No Responses to “VTUS Phase 3 data due May. SCMP sNDA filing soon + Pipeline updates for ASTM OXGN RVX IDRA ARIA”

Leave a Reply